Redx Pharma to present new Phase 2a data for zelasudil (RXC007) at ERS

REDX PHARMA LIMITED ("Redx" or the “Company") Redx to present new data for zelasudil (RXC007) for the treatment of Idiopathic Pulmonary Fibrosis at ERS The oral presentation “Phase 2a signal searching study with zelasudil in idiopathic pulmonary fibrosis (IPF)” will be presented on Sunday 28 September Alderley Park, UK, 22 September 2025 Redx Pharma, the clinical-stage biotechnology company focused on developing novel, small molecule, targeted therapeutics for fibrotic disease, will present new data from the zelasudil Phase 2a signal searching study in idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society (ERS) meeting in Amsterdam. The oral presentation will be given by Professor Toby Maher, zelasudil Phase 2 Chief Investigator and Professor of Clinical Medicine and Director of the Interstitial Lung Disease Programme at Keck School of Medicine at the University of Southern California. Zelasudil is a potent, oral, small molecule, selective, Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor. The Phase 2a study assessed safety, tolerability, pharmacokinetic and initial efficacy in patients with IPF. IPF is a debilitating disease of the lungs which progressively causes scarring and a reduction in lung function. Occurring primarily in older adults (>50 years old), it involves irreversible and variable scarring, stiffening, and thickening of the lung tissues, leading to patients experiencing shortness of breath and lack of oxygen absorption. Over 170,000 patients suffer with IPF i and around a further 53,000 people are diagnosed each year (US, 5 EU, Japan). Patients diagnosed with IPF have an estimated lif e expectancy of 3 to 5 years ii. There is no known cure and current treatment only slows progression of the disease. Oral Presentation Details: Title: Phase 2a signal searching study with zelasudil in idiopathic pulmonary fibrosis (IPF) Session: Emerging Clinical Trials in Pulmonary Fibrosis Day/Date:  Sunday 28 September 2025 Presentation Time: 11:05-11:15 CEST Location: RAI Amsterdam, Europaboulevard, 1079 MW Amsterdam, Netherlands from 27 September to 1 October, 2025 For further information, please contact: Redx Pharma Limited Cailtin Pearson, Head of Communications [email protected] T: +44 (0)1625 469 918 FTI Consulting T: +44 (0)203 727 1000 Simon Conway/ Ciara Martin About Redx Pharma Limited Redx Pharma is a clinical -stage biotechnology company focused on the development of novel, small molecule, targeted medicine for the treatment of fibrotic disease. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry-leading ROCK inhibitor portfolio through the clinic, comprising of zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis, and RXC008, a GI -restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development. The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry, translational science and clinical development , enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not on ly by its wholly-owned clinical-stage product candidates and discovery pipeline, but a lso by its strategic transactions, which include the sale of pirtobrutinib (RXC005, LOXO -305), the only non -covalent or reversible BTK inhibitor , now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals. i Patient numbers (diagnosed prevalence) & market size forecast data sourced from Global Data (US, EU5, Japan) ii Clinical Estimates from Hyun 2015, Ley 2012, Raghu 2006

The release as fetched from its publisher. redxpharma.com ↗